- Home
- JAZZ vs WES Comparison
JAZZ vs WES Comparison
Compare JAZZ & WES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAZZ | WES |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 17.3B |
| IPO Year | 2007 | 2012 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | WES |
|---|---|---|
| Price | $244.79 | $41.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 15 |
| Target Price | ★ $295.86 | $49.15 |
| AVG Volume (30 Days) | 771.2K | ★ 1.8M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 9.04% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | $1,618,693,000.00 | ★ $3,843,403,000.00 |
| Revenue This Year | $12.59 | $22.84 |
| Revenue Next Year | $5.11 | $3.74 |
| P/E Ratio | $6,151.50 | ★ $14.73 |
| Revenue Growth | N/A | ★ 6.61 |
| 52 Week Low | $136.56 | $38.44 |
| 52 Week High | $266.38 | $50.07 |
Technical Indicators
Market Signals| Indicator | JAZZ | WES |
|---|---|---|
| Relative Strength Index (RSI) | 65.72 | 34.60 |
| Support Level | $236.70 | $40.10 |
| Resistance Level | $250.49 | $42.91 |
| Average True Range (ATR) | 7.18 | 1.04 |
| MACD | 4.64 | -0.35 |
| Stochastic Oscillator | 95.81 | 26.42 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About WES Western Midstream Partners LP
Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma) and Texas.